Management will lead a virtual session at the 11th Annual Needham MedTech & Diagnostics 1x1 Conference on August 10. This will be followed by a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, starting at 11:30 AM ET. Investors can access a live webcast of the Boston presentation through the company’s investor relations portal, with a replay remaining available for 30 days.

Lucid Diagnostics specializes in early detection tools for patients suffering from chronic gastroesophageal reflux disease. Its primary offerings, the EsoGuard DNA test and the EsoCheck cell collection device, are designed to identify esophageal precancer during noninvasive office procedures. By targeting the millions of individuals at risk for esophageal cancer, the company aims to establish a standard for preventative diagnostics.